TILT Biotherapeutics (Tiltbio) is a clinical-stage biotechnology company creating the next generation of immunotherapies for solid tumors.
Tiltbio is reshaping cancer treatment by developing innovative investigational therapies that are intended to offer hope to patients with limited treatment options, with an initial focus on platinum-resistant ovarian cancer.
The patented TILT® technology delivers modified viruses intravenously to cancer cells, helping the immune system recognize and attack solid tumors. Intravenous delivery offers the efficiency of the TILT® technology reaching the whole body, potentially targeting primary and metastatic tumors.
Boosting the Body’s Ability to Fight Ovarian Cancer
For patients with platinum-resistant ovarian cancer in whom surgery and chemotherapy have not been effective, Tiltbio is developing an investigational therapy that may offer another option.
Here’s how it works:
- Tiltbio’s technology has been used in Phase I clinical studies in patients with platinum-resistant or refractory ovarian cancer to turn immunologically “cold” tumors (those lacking significant immune-cell infiltration) to “hot” tumors that are active sites for an immune response.
- TILT® technology consist of delivering proprietary oncolytic viruses armed with molecules like cytokines to cancer cells, to help stimulate and enhance T-cell (immune cell) responses.
- TILT-123 (igrelimogene litadenorepvec), Tiltbio’s investigational therapy for platinum-resistant ovarian cancer, is designed for intravenous administration and is the only engineered oncolytic virus armed with two immunostimulatory cytokines: tumor necrosis factor (TNF) and interleukin-2 (IL-2).
Discover more about how Tiltbio’s technology works:
Boosting the Body’s Ability to Fight Ovarian Cancer
For patients with platinum-resistant ovarian cancer in whom surgery and chemotherapy have not been effective, Tiltbio is developing an investigational therapy that may offer another option.
Here’s how it works:
- Tiltbio’s technology has been used in Phase I clinical studies in people with platinum-resistant or refractory ovarian cancer to turn immunologically “cold” tumors (those lacking significant immune-cell infiltration) to “hot” tumors that are active sites for an immune response.
- TILT® technology consist of delivering proprietary oncolytic viruses armed with molecules like cytokines to cancer cells, to help stimulate and enhance T-cell (immune cell) responses.
- TILT-123 (igrelimogene litadenorepvec), Tiltbio’s investigational therapy for platinum-resistant ovarian cancer, is designed for intravenous administration and is the only engineered oncolytic virus armed with two immunostimulatory cytokines: tumor necrosis factor (TNF) and interleukin-2 (IL-2).
Discover more about how Tiltbio’s technology works:
Pipeline
Tiltbio has a pipeline of multiple oncolytic viral therapies for solid tumors. The lead investigational asset, TILT-123, is a cytokine-armed oncolytic adenovirus currently in Phase I/II development in Europe and the U.S. both as a monotherapy and in combination with other immunotherapies like immune checkpoint inhibitors or tumor-infiltrating lymphocyte (TIL) therapy.
Partners
As a leading company developing oncolytic immunotherapies to enable T-cell therapy for solid tumors, Tiltbio collaborates with pharmaceutical companies to generate data on the potential of several combination therapy options.